Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (301-310 of 336) with videos related to

Pageof 34
Sort By:
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Therapeutic Advances in Medical Oncology|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Pageof 34

Showing results (301-310 of 336) with videos related to

Sort By:
Pageof 34
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Therapeutic Advances in Medical Oncology|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Pageof 34